WAO News and Notes - Medical Reviews
Volume 5, Issue 9 Reviews - September 2008
Announcing the WAO Web Site's new look at www.worldallergy.org
Medical Journal Reviews

Prof. Richard F. Lockey, MD, WAO Web Editor-in-Chief, and Guest Editor Mark Glaum, MD PhD, reviewed premier medical journal articles for practicing allergists. WAO 編集委員長 Richard Lockey 教授と Mark Glaum 博士によるアレルギー実地医家のための今月の医学雑誌レビュー。

To read translations of past Medical Journal Reviews, click here.  過去の医学雑誌レビューはこちら。

1. DEFECTIVE KILLING OF STAPHYLOCOCCUS AUREUS IN ATOPIC DERMATITIS IS ASSOCIATED WITH REDUCED MOBILIZATION OF HUMAN B-DEFENSIN-3 (HBD-3)
Synthesis and mobilization are necessary for the rapid elimination of S aureus. In this study, keratinocytes from skin biopsies from subjects with AD vs normals were compared. AD vs normal individual keratinocytes were defective in killing S aureus (P < .001). The constitutive levels of HBD-3 in the epidermal keratinocytes were similar in the 2 groups. However, AD cells were unable to mobilize HBD-3 efficiently to kill S aureus. HBD-3 mobilization and the ability to kill S aureus were significantly inhibited by IL-4 and IL-13 (P < .05). Antagonism of IL-4/10/13 with antibodies significantly improved mobilization of HBD-3 onto the surface of S aureus by skin from patients with AD (P < .01). The authors conclude that AD subjects have problems with S aureus skin infections as a result of increased levels of TH2 cytokines, which inhibit keratinocyte mobilization of HBD-3. Editor's comment: The vexing problem of atopic dermatitis becomes more complex. Perhaps methods to interfere with IL-4 and IL-13 would be beneficial for patients with this disease. Kisich KO, et al., JACI 2008; 122:62.

IL-4/IL-13 でケラチノサイトを処理すると、抗菌ペプチドであるβディフェンシンの分泌が低下することが報告され、そして、これがアトピー性皮膚炎表皮における黄色ブドウ球菌常在化のメカニズムの一つであることが想定されている。本研究においては、アトピー性皮膚炎患者から皮膚生検により得られたケラチノサイトが、正常対照ケラチノサイトに比較して、βディフェンシン -3(HBD-3) の恒常的な分泌は変化がなかったものの、 HBD-3 が有効に拡散しないため殺菌作用が低下していることがわかった。 IL-4/10/13 の作用を抗体で遮断すると、 HBD-3 はアトピー性皮膚炎表皮の黄色ブドウ球菌表面に付着できることがわかった。

2. RITUXIMAB (R) AND INTRAVENOUS IMMUNE GLOBULIN (IVIG) FOR DESENSITIZATION DURING RENAL TRANSPLANTATION
20 highly sensitized (high HLA antibody titers or with donor-specific antibodies) received RX with IVIG and R (a chimeric anti-CD20 monoclonal antibody that reduces B cell and antibody levels). The mean panel-reactive antibody level was 44±30% after the second infusion of IVIG vs a 77±19% pretreatment level (P < 0.001). 16 of the 20 patients (80%) received a transplant, and at 12 months, the mean creatinine level was 1.5±1.1 mg per deciliter and the mean survival rates of patients and grafts were 100% and 94%, respectively. At study entry, the mean dialysis time for recipients to receive a transplant from a deceased donor was decreased from 144±89 months to 5±6 months. There were no serious adverse events, infections, or neurologic problems. This approach may represent a breakthrough in the care of sensitized persons awaiting transplantation who are currently on a much longer waiting list than non-sensitized patients and who often die because of this problem. Editor's comment: This appears to be a major breakthrough for patients who until now have been the least likely to receive renal transplants. Vo AA, et al., N Engl J Med 2008; 359:242. (editorial: Shapiro, pp. 305).

腎臓移植後に、HLAやドナー特異的抗体価が高度の上昇した患者に対して、Rituximab(抗B細胞CD20抗体)と大量γグロブリン静注の投与を行った。その結果、抗体価は半分以上減少し、80%の患者は12ヶ月後も移植片を受け入れていた。編集者注:腎臓移植の治療法に関するブレーク・スルーである。

3. MAST CELL (MC) ACTIVATORS: A NEW CLASS OF HIGHLY EFFECTIVE VACCINE ADJUVANTS
Reviewed by Mark C. Glaum, MD, PhD
MCs have emerged as prominent effectors of lymphocyte activation and immune cell migration to draining lymph nodes. To explore the role of MC in the development of humoral immune responses, investigators combined small-molecule MC activators with vaccine antigens and measured changes in antigen-specific immunoglobulin responses. Subcutaneous and intranasal administration of these combined formulations induces large antigen-specific immunoglobulin G and A responses in vaccinated animals, and this effect appears to depend on MC-dendritic cell interaction and tumor necrosis factor (TNF). Intranasal administration of these formulations provides protection against anthrax lethal toxin challenge in vitro and against vaccinia virus challenge in vivo. Editor's comment: MC activators may function as vaccine adjuvants by promoting MC-dendritic cell interaction thus boosting protective antigen-specific antibody responses. McLachlan JB, et al., Nat Med 2008;14:536.

マスト細胞は、種々の刺激により、メディエーター遊離を介して炎症をおこすのみならず、免疫応答を引き起こす樹状細胞やリンパ球を引き寄せることが判明している。本研究において、著者らは、マウスをもちいて、炭疽菌ワクチン接種を行う際に、経皮的あるいは経鼻的にマスト細胞を活性化させる低分子アジュバントを投与したところ抗体価の有意な上昇がみられたとしている。これら低分子物質は注射の必要もないため、臨床応用範囲は広いと思われる。

4. EPINEPHRINE: THE DRUG OF CHOICE FOR ANAPHYLAXIS - A STATEMENT OF THE WORLD ALLERGY ORGANIZATION (WAO)
WAO has targeted anaphylaxis as a disease which is inappropriately and under treated. This statement discusses the definition of anaphylaxis, following WAO nomenclature, and emphasizes the absolute need for epinephrine to treat this acute allergic emergency. There is some disagreement among the panel members who contributed to this paper about when epinephrine should be given in the course of progressive anaphylaxis. The majority of authors thought it should be given at the earliest sign or symptom of anaphylaxis, particularly, when associated with SCIT, while others felt that such treatment could be delayed until more definitive signs of anaphylaxis are present. Editor's comment: This article will help each physician understand the pharmacology of epinephrine, why it is essential for the successful treatment of anaphylaxis, and when it should be administered. Kemp SF, et al., WAO Journal 2008; Suppl 2: S18. Conflict: the Editor is one of the senior authors.

世界アレルギー機構は、アレルギー疾患の中でもアナフィラキシーの治療には大きな問題があるとしてステートメントを発表している。特に、アナフィラキシーの症状が明確でない場合はエピネフリンによる治療が遅れることが問題であり、医師はエピネフリンのアナフィラキシー治療への必要性にかんする薬理を十分理解しなくてはならない。

5. COMBINATION FLUTICASONE AND SALMETEROL (FP/SAL) VERSUS FIXED DOSE COMBINATION BUDESONIDE AND FORMOTEROL (BUD/F) FOR CHRONIC ASTHMA IN ADULTS AND CHILDREN (REVIEW)
The objective of this paper is to estimate the relative effects of FP/SAL and BUD/F in terms of asthma control, safety and lung function. To do so, randomized studies comparing fixed dose FP/SAL and BUD/F for a minimum of 12 weeks were reviewed for three primary outcomes: i) exacerbations requiring oral glucocorticoid bursts, ii) hospital admission, and iii) serious adverse events. 5537 participants from five studies were analyzed and the odds ratio of exacerbation requiring oral glucocorticoids did not differ significantly between treatments. Likewise, neither did hospital admissions or adverse events. Secondary outcomes also did not differ significantly and include lung function outcomes, symptoms, and rescue medication use. The authors state that the confidence intervals reported do not exclude clinically important differences between treatments in reducing exacerbations or causing adverse events. Likewise, the width of the confidence intervals for the primary outcomes justifies additional trials to better determine the relative effects of these drug combinations. Editor's comment: Thus far, treatment outcomes for fixed combinations of long-acting beta-agonists and ICS do not seem to differ. Lasserson TJ, et al., The Cochrane Collaboration, The Cochrane Library 2008; Issue 3.

フルチカゾンとサルメテロール合剤とブデソニドとフォルモテロール合剤について、ランダム比較した結果、治療を必要とする発作回数など、いずれのアウトカムにも差がなかったとするコクランライブラリーの報告である。

6. USE OF MULTIPLE DOSES OF EPINEPHRINE (E) IN FOOD-INDUCED ANAPHYLAXIS IN CHILDREN
A total of 413 anonymous questionnaires distributed to families of children with food allergies during allergy outpatient visits were analyzed. 78 children (median, 4.5 yrs of age; range, 0.5 - 17.5 yrs) reported 95 reactions for which E was administered. Two doses of E were given in 12 (13%) and three doses in 6 (6%). Peanut, tree nuts, and cow's milk were responsible for >75% of these reactions requiring E. Patients with asthma were more likely to receive multiple doses of E (P = .027). The amount of food ingested or a delay in the initial E were not risk factors for multiple doses. The second dose was administered by a healthcare professional in 94% of the reactions. The authors conclude that 19% of food-induced anaphylactic reactions were treated with more than one dose of E and that prospective studies are necessary to establish risk factors for prescribing multiple E autoinjectors for children with food allergy. Editor's comment: Multiple E autoinjectors should be prescribed for food-induced anaphylaxis. Järvinen KM, et al., JACI 2008; 122:133.

413の食物アレルギー患児家族に対するアンケート調査の結果、78名の患児が95回のエピネフリン投与を必要とするアナフィラキシーをおこしていた。アナフィラキシーの19%は2回以上エピネフリン注射を必要とし、多くはピーナッツ、ナッツ類と牛乳であった。

7. COMPARISON OF A COMBINATION OF TIOTROPIUM (T) PLUS FORMOTEROL (F) TO SALMETEROL (S) PLUS FLUTICASONE (F) IN MODERATE COPD
605 patients with moderate COPD were randomized and treated in a 6-week multicenter, randomized, double-blind, parallel-group study to compare lung function with T, 18 µg qd, plus f, 12 µg bid, to S, 50 µg bid, plus F, 500 µg bid. A total of 592 patients (baseline FEV1, 1.32 ± 0.43 L/min) were analyzed and the 12-h lung function profiles in the T + F were statistically greater than those in the S + F. Differences in FEV1 and FVC at peak and each individual time point were all statistically significant in favor of TF. Predose FVC was significantly higher with the TF combo. The authors conclude that T + F is superior to S + F in patients with moderate COPD. Editor's comment: S probably should be added to T or vice-versa before adding an inhalational glucocorticosteroid for moderate COPD. Rabe KF, et al., Chest 2008; 134:255.

COPDに対するチオトロピウムとフォルモテロールの併用療法をサルメテロールとフルチカゾンの合剤の効果と呼吸機能を測定し比較検討した結果、チオトロピウムとフォルモテロールの併用療法の改善効果が優っていた。

8. LONG TERM PROGNOSIS IN PRESCHOOL CHILDREN WITH WHEEZE: LONGITUDINAL POSTAL QUESTIONNAIRE STUDY 1993-2004
The object of this study was to follow a population of preschool children with and without a history of wheeze (as reported by their parents) for 6-11 years to determine prognosis and important predictive factors. 628 children aged less than five years at recruitment and with at least six years follow-up data were analyzed from two general practice populations in Great Britain. 201 (32%) parents reported wheeze at baseline, 27% of whom still had the symptom on the second occasion (persistent asthma). Predictors of persistent asthma were exercise induced wheeze (OR 3.94, 95% CI 1.72 to 9.00) and a history of atopic disorders (OR 4.44, 95% CI 1.94 to 10.13). If both predictors were present, it indicates a likelihood of 53.2% of developing asthma; whereas if one was present, the likelihood decreased to 17.2%, and neither present, the likelihood decreased even further to 10.9%. Family history was not predictive of persistent asthma. The authors conclude that a history of atopic disorders and exercise induced asthma are good predictors of asthma persisting into the future. Editor's comment: Here's new data indicating that exercise induced asthma and atopic disease early in life are good predictors of asthma in the future. Frank PI, et al., BMJ 2008; 336:1423.

喘鳴のみられた就学前小児のその後の経過について追跡調査が行われた。学童期以降に喘息症状が持続する患児の就学前時期の特徴は、運動誘発喘息発作(OR3.94)および、アトピー疾患の既往歴(OR4.44)であった。編集者注:運動誘発喘息は喘息発症、持続に関する新しいマーカーである。

9. THE DEVELOPMENT OF ALLERGIC INFLAMMATION
This article in Nature is a superb review of allergic inflammation with the following sections: Allergy and Gene-Environment Interactions; Allergen Sensitization and Epithelial Barriers; Features of Allergic Inflammation; IgE and the Exacerbation of Allergic Disorders; Suppression and Resolution of Allergic Inflammation; and Management of Allergies and Allergic Inflammation. It ends with a section on "What Next?", implying that molecular biology will alter the treatment of allergic diseases. Perhaps the most wonderful thing about this review is the extraordinary six figures included in the article. Editor's comment: This is a wonderful review and update for all physicians, no matter what their degree of knowledge about allergic inflammation. Galli SJ, et al., Nature 2008; 454:445.

感作の段階から慢性炎症、気道リモデリングまでをわかりやすく、かつ、最新の情報を盛り込んで解説している。6つの図は秀逸である。

10. SUBLINGUAL IMMUNOTHERAPY (SLIT) FOR LARGE LOCAL REACTIONS CAUSED BY HONEYBEE STING: A DOUBLE-BLIND, PLACEBO-CONTROLLED (DBPC) TRIAL
26 of 30 patients completed a SLIT randomized, DBPC study of large local reactions. After the baseline sting challenge, they were randomized to SLIT or placebo for six months. After a 6-week build-up period, they were maintained with 525 µg (35 µg every other day) of venom monthly. The sting challenge was repeated after six months. The median of the peak maximal diameter of the LLRs decreased from 20.5 to 8.5 cm (P = .014), whereas no change was seen in the placebo group (23.0 vs 20.5 cm, I = ns). There was one dropout in the active and three in the placebo group. No adverse reactions were reported. The authors call for more SLIT dose-ranging studies and studies of systemic reactions. Editor's comment: This study of LLRs is encouraging and may indicate that SLIT could be beneficial for systemic reactions to Hymenoptera insects. Severino MG, et al., JACI 2008; 122:44.

ハチ毒に対する舌下免疫療法をハチ毒による局所反応を指標としてプラセボ比較で検討した。その結果、局所反応は実薬群では20.5cmから8.5cmへ有意に改善したのに対し、プラセボ投与群では変化がみられなかった。

World Allergy Congress (WAC) 2009 - Buenos Aires, Argentina,  6-10 December 2009

Special Announcement to all Current Members of WAO Member Societies

wao journalTo receive the World Allergy Organization Journal for free, current Members of WAO Member Societies must access the journal through the WAO Web site. Click "Members Only" and you will be provided with instructions on how to get free access to all articles published in the World Allergy Organization Journal.

WAO ジャーナルは、メンバー(日本アレルギー学会員は全員メンバー)に対して上記 web< サイトで無料で公開されている。

Allergy Book Review

The Asthma Educator's Handbook
Authors: Fanta CH, Stieb ES, Carter EL, Haver KE
ISBN-10: 0071447377
ISBN-13: 978-0071447379

喘息教育のためのハンドブックの紹介である。冗長で教訓的であるが、患者とコミュニケートするには役立つ。医師以外のヘルスケアの人たちに適しているとしている。

Available from: The McGraw-Hill Companies, Inc. 2007
List Price: $52.95

Reviewer:
Pavana Beerelli, MSIV
George Washington University
School of Medicine

Description
The handbook reviews fundamentals of the pathology, diagnosis, staging, and treatment of asthma. A discussion of the clinical applications of asthma care allows one to gain confidence in asthma management through this evidence-based textbook.

Purpose
Proper skills, resources, and emphasis on the importance of asthma care are the book's main goals, designed to prepare healthcare professionals for certification as asthma educators. Most texts are too lengthy and lack the tools to reinforce the didactic information; however, this text facilitates learning and provides ways to effectively communicate information to patients and their families.

Audience
The handbook is targeted to all healthcare professionals who work with pediatric and adult asthma. It focuses on many practical situations that patients and/or their family members need to know about.

Features
The ten chapters are covered with patient-friendly terminology eliminating the language barrier that often is present between medical personnel and patients. The book is well organized, referenced, and the diagrams and tables allow the reader to emphasize certain learning points within the text. Key points highlight important concepts. Self-assessment multiple-choice questions with detailed answers finalize each chapter in a wonderful manner.

Assessment
This book teaches physicians and other healthcare professionals how to recognize and treat asthma exacerbations and was inspired by patients and their experiences with this disease. It is designed for the informed educator who knows a fair amount about asthma while focusing on patient needs. In summary, it is an excellent resource for the asthma educator.

Find more allergy book reviews on the WAO Website here.

The World Allergy Organization's mission is to be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training, as a world-wide alliance of allergy and clinical immunology societies. Visit us on the Web at www.worldallergy.org

World Allergy Organization (WAO)
Secretariat
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202-3823
Email: info@worldallergy.org

You have received this message because you are a member of a WAO Member Society; you have subscribed for the monthly e-letter or had previous contact with the World Allergy Organization. If you would prefer not to receive further messages from WAO, please replay to this message with REMOVE in the subject line.

Made possible through an unrestricted educational grant from Novartis.
novartis